US 12,331,110 B2
Monoclonal antibodies against endotrophin and the use thereof
Ningyan Zhang, Houston, TX (US); Dawei Bu, Dallas, TX (US); Zhiqiang An, Houston, TX (US); Hui Deng, Houston, TX (US); and Philipp E. Scherer, Dallas, TX (US)
Assigned to THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Appl. No. 17/273,538
Filed by THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
PCT Filed Sep. 5, 2019, PCT No. PCT/US2019/049653
§ 371(c)(1), (2) Date Mar. 4, 2021,
PCT Pub. No. WO2020/051275, PCT Pub. Date Mar. 12, 2020.
Claims priority of provisional application 62/727,140, filed on Sep. 5, 2018.
Prior Publication US 2022/0056124 A1, Feb. 24, 2022
Int. Cl. C07K 16/26 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/18 (2006.01)
CPC C07K 16/26 (2013.01) [A61P 35/00 (2018.01); C07K 16/18 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 14 Claims
 
1. A monoclonal antibody or an antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof comprises HCDR1, HCDR2, and HCDR3 amino acid sequences provided in a heavy chain variable domain (VH) amino acid sequence of SEQ ID NO: 157 and LCDR1, LCDR2, and LCDR3 amino acid sequences provided in a light chain variable domain (VL) amino acid sequence of SEQ ID NO: 158.